Ginkgo Bioworks (NYSE: DNA)
Ginkgo Bioworks Return vs. S&P
1 Year | 5 Year | 5 Year Annualized | Since IPO |
---|
Ginkgo Bioworks Company Info
Ginkgo Bioworks Holdings, Inc. is a biotech company. Its platform is market agnostic and enables biotechnology applications across diverse markets, from food and agriculture to industrial chemicals to pharmaceuticals. It operates through the Cell Programming/Foundry, and Biosecurity segments. The company was founded by Jason Kelly, Reshma Shetty, Bartholomew Canton, Austin Che, and Thomas F. Knight, Jr. in 2008 and is headquartered in Boston, MA.
News & Analysis
Should You Buy the Dip on Ginkgo Bioworks Stock?
Its vision is ambitious, but can it actually be made to work?
2 Cathie Wood Biotech Stocks That Could Be Worth the Risk
You don't need to buy her picks, but it's worth understanding them.
3 Things You Need to Know if You Buy Ginkgo Bioworks Today
It needs to work within the constraints imposed by these three issues.
Ginkgo Bioworks Stock Has 37.5% Downside, According to 1 Wall Street Analyst
Ginkgo Bioworks has become a penny stock -- and that's the least of its problems,
Is Ginkgo Bioworks Holdings Stock a Buy?
Can this struggling stock turn things around?
These Are Billionaires’ Favorite Healthcare Stocks
The Motley Fool analyzed 16 billionaire-led hedge funds to get an idea of their healthcare sector investment strategies.
What's the Difference Between Biotech Stocks and TechBio Stocks?
A few enterprising businesses are marketing themselves differently.
Ginkgo's Q1 Earnings Were a Mixed Bag
The cell engineering and biosecurity specialist's sales slumped as a big source of COVID-related revenue dried up.
Valuation
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.